Clinical trials: Endstage Renal Disease
Vitamin K Supplementation, Endstage Renal Disease
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
Cardiovascular disease (CVD) is the most frequent cause of death in patients (ptt.) with chronic kidney disease (CKD). Compared to the general population death due to CVD is 10-20 times higher in CKD ptt.
- Conditions
- Vitamin K Supplementation, Endstage Renal Disease, Cardiovascular Disease, Bone Disease
- Trial name
- RenaKvit (NCT02976246)
- Testing
- Vitamin K2 (MK7)
- Where
- Denmark
- Volunteers
- 123 people
- Sponsor
- Zealand University Hospital
Endstage Renal Disease
Data Collection for Next Generation Ultrasound Technology Development
The study is designed to collect data from a ultrasound device being used to evaluate feasibility of next generation algorithms for ultrasound data processing and does not test any health outcome.
- Trial name
- NCT02946229
- Testing
- Ultrasound scan
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- GE Healthcare
Endstage Renal Disease, Secondary Hyperparathyroidism
Intravenous Paricalcitol in Chronic Hemodialysis Patients
This study aims to provide intravenous paritcalcitol treatment for the sick and poor hemodialysis patients with severe secondary hyperparathyroidism (SHPT) resistant to existing vitamin D analogs therapy or with hypercalcemia…
- Trial name
- NCT03023748
- Testing
- Intravenous Paricalcitol
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Kidney Failure, Chronic
Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients
Diabetes after kidney transplantation is a frequent complication, the incidence of which varies from 7 to 45% depending on the studies and on the diagnostic criteria used.
- Trial name
- GLITTER (NCT03640026)
- Testing
- Tacrolimus
- Where
- 2 sites in France
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Endothelial Dysfunction, Endstage Renal Disease
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
The Purpose of this study is to determine if the Febuxostat has an effect on endothelial dysfunction on hemodialysis patients.
- Trial name
- NCT02866214
- Testing
- Febuxostat
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Endstage Renal Disease
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis.
- Trial name
- ACHIEVE (NCT03020303)
- Testing
- Spironolactone 25Mg Tablet
- Where
- 141 sites in Australia, Brazil and 10 more
- Volunteers
- 2,538 people
- Sponsor
- Hamilton Health Sciences Corporation
Endstage Renal Disease
Parathyroidectomy in Endstage Renal Disease
To test the hypothesis that total parathyroidectomy retards cardiovascular calcification, improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in end-stage renal disease patients on maintenance…
- Trial name
- NCT00745719
- Testing
- parathyroidectomy
- Where
- Hong Kong
- Volunteers
- 122 people
- Sponsor
- The University of Hong Kong
Endstage Renal Disease
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.
- Trial name
- SERENE (NCT00745589)
- Testing
- sevelamer hydrochloride
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Endstage Renal Disease
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
This is a single-center, prospective, open-label, controlled, randomized, cross-over study in 34 prevalent end-stage renal disease patients on chronic hemodialysis treatment with hyperphosphatemia.
- Trial name
- NCT03010072
- Testing
- low-dose sucroferric oxyhydroxide, high-dose sucroferric oxyhydroxide
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Prim. Priv. Doz. Dr. Daniel Cejka
Renal Impairment
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of pasireotide,the PK of pasireotide in subjects with different degrees of renal impairment.
- Trial name
- NCT01578928
- Testing
- SOM230
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Kidney Disease
Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis
Objective: 1. To assess whether nocturnal hemodialysis and renal transplantation are associated with less progression of coronary arterial calcification, compared with conventional hemodialysis and peritoneal dialysis; 2.
- Trial name
- NOCTX (NCT00950573)
- Where
- 2 sites in Netherlands
- Volunteers
- 184 people
- Sponsor
- Dianet Dialysis Centers
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore